Selective estrogen receptor modulators (SERM): A new choice for postmenopausal women and physicians who worry on cancer

  • Ali Baziad
Abstract viewed: 278 times
PDF downloaded: 193 times

Abstract

The postmenopausal state is characterized by the cessation of menstruation, loss of ovarian function, and a dramatic decrease in the level of circulating estrogen. This state of estrogen deficiency contributes to the acceleration of several age-related health problems in women, including cardiovascular disease, osteoporosis, and dementia. Estrogen replacement is clearly effective in the short-term and long-term treatment and prevention of postmenopausal symptoms. However, until now, the amount of HRT user is still very low. Fear of breast cancer and endometrial cancer are the most common concern in using hormone replacement therapy (HRT), although the relationship between long-term HRT and breast cancer remains controversial. For physicians or patients, who worry on cancer, the ideal drug is now available i.e. the selective estrogen receptor modulators (SERM), with the generic name raloxifine. (Med J Indones 2001; 10: 187-90)

Keywords: HRT, raloxifine, osteoporosis, CVD, tamoxifen

Author Biography

Ali Baziad
Department of Obstetics and Gynecology, Faculty of
Medicine, University of Indonesia/Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia
Published
2001-08-01
How to Cite
1.
Baziad A. Selective estrogen receptor modulators (SERM): A new choice for postmenopausal women and physicians who worry on cancer. Med J Indones [Internet]. 2001Aug.1 [cited 2019Nov.12];10(3):187-90. Available from: http://mji.ui.ac.id/journal/index.php/mji/article/view/29
Section
Review Article

Most read articles by the same author(s)